Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 8/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 3/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK7 | P50613 | 2/20 | 0.38 |
| ▸ | CCNH | P51946 | 2/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249000 | 1.00 | GFER (0.42) | GFERTHRBAURKAKMT2ACCNK | |
| SCHEMBL4240923 | 0.90 | GFER (0.40) | GFERTHRBAURKAHRH4GPR6 | |
| SCHEMBL4240926 | 0.90 | GFER (0.40) | GFERTHRBAURKAHRH4GPR6 | |
| SCHEMBL8227626 | 0.89 | GFER (0.45) | GFERTHRBKMT2ACCNKCDK12 | |
| SCHEMBL4241934 | 0.88 | HCRTR1 (0.44) | GFERKMT2ACCNKCDK12CCNA2 | |
| SCHEMBL4241941 | 0.88 | HCRTR1 (0.44) | GFERKMT2ACCNKCDK12CCNA2 | |
| SCHEMBL4244415 | 0.85 | GFER (0.46) | GFERKMT2ACCNKCDK12CCNA2 | |
| SCHEMBL4244423 | 0.85 | GFER (0.46) | GFERKMT2ACCNKCDK12CCNA2 | |
| SCHEMBL4392235 | 0.83 | GFER (0.41) | GFERTHRBCCNKCDK12CCNA2 | |
| SCHEMBL4385982 | 0.82 | HCRTR1 (0.40) | GFERAURKAKMT2ACCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | GFER 607/4885THRB 246/4885AURKA 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.